<DOC>
	<DOCNO>NCT01202734</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety 3 single dos Methylphenidate HCl healthy Japanese adult male volunteer .</brief_summary>
	<brief_title>A Pharmacokinetics Safety Methylphenidate HCl Healthy Japanese Adult Male Volunteers</brief_title>
	<detailed_description>This open-label ( name assign treatment know ) , single-center study pharmacokinetics ( blood level ) safety 3 single dos methylphenidate HCl administer orally ( mouth ) healthy Japanese adult male volunteer . Methylphenidate HCl drug currently approve treatment adult attention-deficit/hyperactivity disorder ( ADHD ) region outside Japan , include United States study conduct . Volunteers participate study maximum 42 day . Blood sample collect volunteer study determine concentration methylphenidate HCl blood dosing . Safety monitor throughout study evaluate adverse event report , change clinical laboratory test result , vital sign measurement , physical examination result , protocol-specified safety assessment . All volunteer receive single oral dose methylphenidate HCl 240 mL ( 1 cup ) noncarbonated water least 10-hour fast ( without eat food ) 3 treatment period follow : Period 1 , one 36-mg tablet ; Period 2 , three 18-mg tablet ; Period 3 , two 36-mg tablet . Treatment period separate 3 7 day . Volunteers continue fast least 4 hour dose .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Body mass index ( BMI ) 18.5 25.0 kg/mÂ² , inclusive Body weight less 50 kg Supine ( lie ) blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic History current medical illness judge investigator clinically significant Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 14 day first dose study drug History drug alcohol abuse within past 5 year History smoking use nicotine contain substance within previous 2 month</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CONCERTA</keyword>
	<keyword>Methylphenidate HCl</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Safety</keyword>
	<keyword>Adult</keyword>
	<keyword>Men</keyword>
	<keyword>Male</keyword>
</DOC>